• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 20, 2018

View Archived Issues

Financings

Moleculin Biotech Inc., of Houston, said it entered a definitive agreement with institutional investors for a registered direct offering of securities with gross proceeds of approximately $9 million. Read More

In the clinic

Wilson Therapeutics AB, of Stockholm, Sweden, said that the first patient has been enrolled in its pivotal phase III trial, called Focus. Read More

Other news to note

Alk-Abelló A/S, of Copenhagen, said that its partner Torii Pharmaceutical Co. Ltd., of Tokyo, gained approval from the Japanese Ministry of Health, Labour and Welfare to expand the use of Miticure, a sublingual allergy immunotherapy tablet, to include treating pediatric allergic rhinitis patients. Read More

News from AAD 2018

Glenmark Pharmaceuticals Inc., of Paramus, N.J., presented findings from a phase IIa study of GBR 830, an investigational anti-OX40 monoclonal antibody that evaluated the safety, biological and clinical activity, and pharmacokinetics of GBR 830 in 64 patients with moderate-to-severe atopic dermatitis (AD). Read More

Bench Press: BioWorld looks at translational medicine

In their rapid division, cancer cells have some similarities to early development, and cells often have embryonic cell-like features. Researchers from Stanford University have shown that those parallels can be exploited to make autologous therapeutic vaccines from induced pluripotent stem cells (iPSCs). Read More

Correction

Read More

Holiday notice

BioWorld's offices were closed in observance of Presidents' Day. Read More

ICER declares costs of approved CAR-T therapies aligned with clinical benefit

A new report published by Boston's Institute for Clinical and Economic Review (ICER) concludes that two pricey new CAR-T cell therapies, Novartis AG's Kymriah (tisagenlecleucel) and Gilead Sciences Inc.'s Yescarta (axicabtagene ciloleucel), both provided moderate certainty of a small to substantial net health benefit compared to commonly used chemotherapies or no therapy at all in their respective indications. Read More

Yale prof: Drug-coupon 'kickbacks' lead to hamstrung PBMs and raise drug costs

A two-part webinar on drug pricing by sponsor USC-Brookings Schaeffer Initiative for Health Policy dragged somewhat during the first half, which dealt with the subject of whether and in what ways to retool Medicare Part D. But the livelier second half – on strategies to reduce cost sharing for commercially insured patients – included a talk by Fiona Scott Morton, professor of economics at the Yale School of Management, who raised some eyebrows on the panel. Read More

Apricus shares tank on yet-another FDA CRL on ED candidate

Shares of Apricus Biosciences Inc. plunged 70 percent Friday on word that the FDA issued another complete response letter (CRL) for the resubmitted new drug application (NDA) of Vitaros (alprostadil, DDAIP.HCl) to treat erectile dysfunction (ED). In late 2016, the San Diego-based company was hopeful that it had found a road forward in the U.S. for Vitaros – approved in Canada and in certain countries in Europe, Latin America and the Middle East – by resolving issues in the CRL dating back to 2008. Read More

Cancer vaccine JV may be first ever between U.S., Cuba

AUSTIN, Texas – Roswell Park Cancer Center is about to form a 50:50 joint venture (JV) with Cuba's Center for Molecular Immunology (CIM) to commercialize cancer vaccines developed by CIM. Read More

As Vertex ascends toward apex, other contenders continue to chase CF

To some observers, Vertex Pharmaceuticals Inc. would seem to have the cystic fibrosis (CF) market wrapped up. With Kalydeco (ivacaftor) and Orkambi (lumacaftor/ivacaftor) already market-leading CF drugs, the Boston-based firm wowed investors and analysts this month with prospects for next-generation correctors, VX-659 and VX-445, which are moving into phase III development as part of separate triple-combination regimens. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • 3D heart in chest

    At CRVBC 2025: Aging is circulating in your blood

    BioWorld Science
    All kinds of substances circulate through the bloodstream. Some are beneficial, like oxygen or nutrients, and others less so, like waste products, toxins,...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe